LifeVantage Announces Results of Protandim(R) Study on Oxidative Stress Presented at Experimental Biology Conference
May 01 2014 - 9:00AM
LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to
helping people achieve healthy living through a combination of a
compelling business opportunity and scientifically validated
products, announced today that its most recent study on Protandim
was presented at the 2014 Experimental Biology Conference held
April 26-30, in San Diego, California.
Experimental Biology is an annual meeting attended by more than
14,000 scientists. The theme at the annual meeting of
professional research scientists was "Transforming the Future
through Science." Researchers from Colorado State University
presented a study entitled Oxidative Stress is Decreased with
Short-Term Protandim Use. The placebo-controlled double-blind study
supplemented 33 overweight/obese adults, ages 45-69 for 30-days
with LifeVantage's Protandim formula currently sold in Japan.
Results indicated a significant reduction in markers of oxidative
stress in subjects receiving this Protandim formulation.
Dr. Shawn Talbott, LifeVantage Chief Science Officer commented,
"We are pleased to see clinical studies involving our unique
products. This research will be added to our large and growing
portfolio of scientific studies and builds on the growing
collection of evidence supporting Nrf2 activation and oxidative
stress reduction associated with Protandim. In addition, this
study demonstrates that both of our formulations of Protandim are
potent oxidative stress reducers. This allows us to offer
people a powerful Nrf2 activator and oxidative stress reduction
product in most jurisdictions."
Abstracts of the conference can be found at the Journal of the
Federation of American Societies for Experimental Biology:
Rebecca Scalzo, Janelle Davis, Joseph Beals, Laurie Biela,
Gregory Giordano, Hunter Paris Benjamin Miller, Karyn Hamilton, and
Christopher Bell, (2014) Oxidative stress is decreased with
short-term Protandim use when piperine is substituted for
ashwagandha (LB399) FASEB J April 28:LB399.
http://www.fasebj.org/gca?allch=&submit=Go&gca=fasebj%3B28%2F1_Supplement%2FLB399
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq:LFVN), a leader in Nrf2 science
and the maker of Protandim(®, the Nrf2 Synergizer® patented dietary
supplement, TrueScienceTM Anti-Aging Skin Care Regimen with
enhanced Nrf2 technologies, and LifeVantage® Canine Health, is a
science based network marketing company. LifeVantage is dedicated
to visionary science that looks to transform wellness and
anti-aging internally and externally with products that
dramatically reduce oxidative stress at the cellular level.
LifeVantage was founded in 2003 and is headquartered in Salt Lake
City, Utah.
Forward Looking Statements
This document contains forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects, as well as
words such as "believe," "hopes," "intends," "estimates,"
"expects," "projects," "plans," "anticipates," "look forward to"
and variations thereof, identify forward-looking statements, but
their absence does not mean that a statement is not
forward-looking. Examples of forward-looking statements include,
but are not limited to, statements we make regarding our ability to
offer our product in certain jurisdictions. Such forward-looking
statements are not guarantees of performance and the Company's
actual results could differ materially from those contained in such
statements. These forward-looking statements are based on the
Company's current expectations and beliefs concerning future events
affecting the Company and involve known and unknown risks and
uncertainties that may cause the Company's actual results or
outcomes to be materially different from those anticipated and
discussed herein. These risks and uncertainties include, among
others, those discussed in greater detail in the Company's Annual
Report on Form 10-K and the Company's Quarterly Report on Form 10-Q
under the caption "Risk Factors," and in other documents filed by
the Company from time to time with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this
document. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this document, except as required by law.
CONTACT: Investor Relations Contact:
Cindy England (801) 432-9036
Director of Investor Relations
-or-
John Mills (310) 954-1105
Partner, ICR, INC
Lifevantage (NASDAQ:LFVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lifevantage (NASDAQ:LFVN)
Historical Stock Chart
From Sep 2023 to Sep 2024